Code Chain New Continent Announces LOI to Acquire Filecoin Mining Assets

PR Newswire

NEW YORK, Sept. 14, 2021 /PRNewswire/ — Code Chain New Continent Limited (the “Company,” or “Code Chain” or “We”) (NASDAQ: CCNC), a leading eco-technology company, today announced that it entered into a non-binding letter of intent (the “LOI”) with Shenzhen Jindeniu Electronics Limited(“Jindeniu”).

Pursuant to the LOI, Code Chain agrees to purchase certain assets, including Filecoin (“FIL”) servers, FIL digital currency PiB computing power, and FIL digital currency (“Target Assets”) from Jindeniu. The total purchase price will be approximately USD 15.9 million, payable in cash.

Following the LOI’s execution, Code Chain will arrange its personnel, representatives, and advisors to perform due diligence on the Target Assets. Upon completion of the due diligence and the Company’s satisfaction of the results, the two parties will enter into a definitive assets purchase agreement within five days. The definitive assets purchase agreement’s execution shall be no later than December 31, 2021.

David (Weidong) Feng, Co-CEO of the Company, stated, “The LOI marks an important step for Code Chain’s Filecoin success. We are excited to continue our efforts in expanding our Filecoin footprint after acquiring China’s Filecoin miner. Filecoin is the native token of the Filecoin Network, a decentralized data-sharing platform that offers a thriving ecosystem of independent storage providers while eliminating barriers. I am confident that this will become the major trend for the industry, and Code Chain is placing itself ahead of the competition.”

About Code Chain New Continent Limited

Code Chain New Continent Limited engages in the research, design, and development of electronic tokens that combine the five-W elements (when, where, who, why, what), geographic location via the Beidou satellite system, and identity information using Code Chain technology. The electronic tokens are unique, tradable, and inheritable digital assets and cannot be tampered with. The electronic tokens are based on and stored in the Code Chain system and can be used to monitor and document all kinds of consumer behaviors that involve code-scanning. The Company has recently diversified its business into Bitcoin mining and is committed to becoming a vertically integrated cryptocurrency miner.


Safe Harbor Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals, and projections, which are subject to numerous assumptions, risks, and uncertainties. These forward-looking statements may include, but are not limited to, statements containing words such as “may,” “could,” “would,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “expects,” “intends”, “future” and “guidance” or similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to change at any time. These forward-looking statements are based upon management’s current expectations and are subject to a number of risks, uncertainties and contingencies, many of which are beyond the Company’s control that may cause actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The Company’s actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including those described under the heading “Risk Factors” in the Company’s public filings with the Securities and Exchange Commission, including the Company’s annual report on 10-K. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required under applicable law.

Cision View original content:https://www.prnewswire.com/news-releases/code-chain-new-continent-announces-loi-to-acquire-filecoin-mining-assets-301375925.html

SOURCE Code Chain New Continent Limited

TDS Announces Redemption Of 5.875% Senior Notes Due 2061

PR Newswire

CHICAGO, Sept. 14, 2021 /PRNewswire/ — Telephone and Data Systems, Inc. (NYSE: TDS) today announced that it will redeem all of its outstanding 5.875% Senior Notes due 2061 (NYSE: TDA) (the “TDA Notes”).  The $195 million aggregate principal amount of outstanding TDA Notes will be redeemed October 14, 2021, at a redemption price of 100 percent of the principal amount ($25 face value per unit), together with accrued and unpaid interest to the redemption date.  The paying agent is The Bank of New York Mellon.

“After the successful completion of our recent preferred offering, we are opportunistically redeeming this debt to realize additional interest savings, as we now have ample liquidity to fund our fiber expansion,” said Peter L. Sereda, TDS executive vice president and chief financial officer.

A notice of redemption with instructions is being distributed to registered holders of the notes. Beneficial holders with any questions about the redemption should contact their respective brokerage firm or financial institution that holds notes on their behalf.

About TDS
Telephone and Data Systems, Inc. (TDS), a Fortune 1000® company, provides wireless; broadband, video and voice; and hosted and managed services to approximately 6 million connections nationwide through its businesses, UScellular, TDS Telecom, and OneNeck IT Solutions. Founded in 1969 and headquartered in Chicago, TDS employed approximately 8,900 associates as of June 30, 2021.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: All information set forth in this news release, except historical and factual information, represents forward-looking statements. This includes all statements about the company’s plans, beliefs, estimates, and expectations. These statements are based on current estimates, projections, and assumptions, which involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Important factors that may affect these forward-looking statements include, but are not limited to: intense competition; the ability to obtain or maintain roaming arrangements with other carriers on acceptable terms; the ability to obtain access to adequate radio spectrum to meet current or anticipated future needs, including participation in FCC auctions; the ability to attract people of outstanding talent throughout all levels of the organization; TDS’ smaller scale relative to larger competitors; changes in demand, consumer preferences and perceptions, price competition, or churn rates; advances in technology; impacts of costs, integration problems or other factors associated with acquisitions, divestitures or exchanges of properties or wireless spectrum licenses and/or expansion of TDS’ businesses; the ability of the company to successfully construct and manage its networks; difficulties involving third parties; uncertainties in TDS’ future cash flows and liquidity and access to the capital markets; the ability to make payments on TDS and UScellular indebtedness or comply with the terms of debt covenants; conditions in the U.S. telecommunications industry; the value of assets and investments; the state and federal regulatory environment; pending and future litigation; cyber-attacks or other breaches of network or information technology security; disruption in credit or other financial markets; deterioration of U.S. or global economic conditions; the impact, duration and severity of public health emergencies, such as the COVID-19 pandemic. Investors are encouraged to consider these and other risks and uncertainties that are more fully described under “Risk Factors” in the most recent filing of TDS’ Form 10-K, as updated by any TDS Form 10-Q filed subsequent to such Form 10-K.    

For more information about TDS and its subsidiaries, visit:
TDS: www.tdsinc.com 
UScellular: www.uscellular.com 
TDS Telecom: www.tdstelecom.com 
OneNeck IT Solutions: www.oneneck.com

 

Cision View original content:https://www.prnewswire.com/news-releases/tds-announces-redemption-of-5-875-senior-notes-due-2061–301376096.html

SOURCE Telephone and Data Systems, Inc.

Celsius to Participate at the 4th Annual Wells Fargo Consumer Conference

PR Newswire

BOCA RATON, Fla., Sept. 14, 2021 /PRNewswire/ — Celsius Holdings, Inc., (Nasdaq: CELH), maker of the leading global fitness drink, CELSIUS®, today announced that management will be participating at the 4th Annual Wells Fargo Consumer Conference. The Company’s management will host a series of institutional investor meetings throughout the day on Wednesday, September 22, 2021. The conference will be held at the Ritz-Carlton Laguna Niguel, Dana Point, California.


About Celsius Holdings, Inc.

Celsius Holdings, Inc. (Nasdaq: CELH), is a global company with a proprietary, clinically proven formula for its master brand CELSIUS® and all its sub-brands. A lifestyle fitness drink and a pioneer in the rapidly growing performance energy sector, CELSIUS® has five beverage lines that each offer proprietary, functional, healthy-energy formulas clinically-proven to offer significant health benefits to its users. The five lines include, CELSIUS® Originals, CELSIUS HEAT™, CELSIUS® BCAA +Energy,  CELSIUS® On-the-Go, and CELSIUS® Sweetened with Stevia. CELSIUS® has zero sugar, no preservatives, no aspartame, no high fructose corn syrup, and is non-GMO, with no artificial flavors or colors. The CELSIUS® line of products is Certified Kosher and Vegan. CELSIUS® is also soy and gluten-free and contains very little sodium. CELSIUS® is backed by six university studies that were published in peer-reviewed journals validating the unique benefits CELSIUS® provides. CELSIUS® is sold nationally at Target, CVS, Walmart, GNC, Vitamin Shoppe, 7-Eleven, Dick’s Sporting Goods, The Fresh Market, Sprouts and other key regional retailers such as HEB, Publix, Winn-Dixie, Harris Teeter, Shaw’s and Food Lion. It is also available on Amazon, at fitness clubs and in select micro-markets across the country. For more information, please visit: http://www.celsiusholdingsinc.com

Investor Relations:
Cameron Donahue
(651) 707-3532
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/celsius-to-participate-at-the-4th-annual-wells-fargo-consumer-conference-301375759.html

SOURCE Celsius Holdings, Inc.

RecoveryOne Closes $33 Million Series C Financing

Company to Scale Business and Accelerate Market Expansion Efforts

PR Newswire

WALNUT CREEK, Calif., Sept. 14, 2021 /PRNewswire/ — RecoveryOne, a leading innovator in evidence-based solutions that personalize and improve the path to recovery from musculoskeletal (MSK) conditions, today announced completion of a $33 million Series C funding round co-led by Cobalt Ventures, a wholly-owned subsidiary of Blue Cross and Blue Shield of Kansas City (Blue KC), and TELUS Ventures, the strategic investment arm of Canadian telecommunications and health technology company TELUS. The Series was rounded out by Cigna Ventures, 7wireVentures, and Leverage Health Solutions.

RecoveryOne_Logo

Our sustained efforts to transform the recovery journey have brought us to this moment.

As the largest provider of digital musculoskeletal (MSK) recovery programs for payers and their members, in addition to widely supporting employer populations, RecoveryOne will utilize the investment capital to fuel continued growth in the payer and employer markets.

Since the company’s founding, RecoveryOne has established their solution as the exemplar for full-body musculoskeletal (MSK) recovery by concentrating efforts on consumer satisfaction, engagement, clinical outcomes, and recovery rates. As a result, they created an unparalleled experience and simultaneously demonstrated significant savings in total medical costs, which have been independently measured by RecoveryOne clients in case-matched, risk-adjusted studies.

“Excelling at MSK care delivery is our mission,” said RecoveryOne CEO Mark Luck Olson. “Our sustained efforts to transform the recovery journey have brought us to this moment where we can clearly see the powerful impact we have on the lives of those suffering from MSK conditions. We are creating ongoing value for consumers, caregivers, health plans, and payers, so this funding round will help us to scale those efforts and extend our impact far beyond the 60+ clients and nearly three million consumers under contract today.”

David Eichler, Cobalt Ventures President and Managing Partner added, “Digital health innovations that lower total cost of care for payers while improving access, engagement and experience for members are a natural extension of our healthcare portfolio. We foresee great opportunities for our partnership with RecoveryOne”.

Mario Mele, TELUS Ventures Vice President of Corporate Strategy commented, “We are impressed with the clear vision shared across the RecoveryOne team. We invest in disruptive, market-transforming companies to help drive better health outcomes. RecoveryOne has tapped into a critical and ongoing market need by delivering an innovative, effective, and affordable solution that is making a difference in people’s lives and will continue to do so in the future.”

The Series C funding builds on a groundbreaking year for RecoveryOne in terms of growth across employer populations. These advances are demonstrated by employer renewals and retention rates of over 90%. In addition, the RecoveryOne virtual MSK program was included as a standard benefit by a major national payer, designed to improve the cost and quality of care at scale for millions of members.

About RecoveryOne
RecoveryOne is a recovery-focused virtual physical therapy solution for employers, partners, and health plans. In reinventing MSK care delivery, we have created evidence-based programs rich in human-connected care and amplified through technology that help members from head to toe and everything in between. RecoveryOne is reimagining conventional MSK recovery by giving users a highly engaging and tailored experience that reduces costs and speeds recovery. For more information, visit RecoveryOne.com and follow us on LinkedIn.

About Cobalt Ventures, LLC

Cobalt Ventures, LLC is the strategic venture capital arm of Blue Cross and Blue Shield of Kansas City, the largest not-for-profit health insurer in Missouri and the only not-for-profit commercial health insurer in Kansas City. Cobalt invests in high growth companies that align with Blue KC’s mission and can scale nationally across the payer industry.  Cobalt actively partners with entrepreneurs in bringing innovative solutions to healthcare that increase overall quality, improve outcomes, and lower costs for customers and members.  More information about Cobalt Ventures can be found at http://www.cobalt-ventures.com.

About TELUS Ventures
As the strategic investment arm of TELUS Corporation (TSX: T, NYSE: TU), TELUS Ventures is one of Canada’s most active corporate venture capital funds. TELUS Ventures invests globally in companies from Seed to Pre-IPO with a focus on innovative technologies such as AgTech, HealthTech, Connected Consumer, IoT, AI, and Security to actively drive new solutions across the TELUS ecosystem. Led by a team of experienced operators, investors and executives, the Ventures team is passionate about creating positive social impact through financial tools and has invested in more than 90 companies since inception.

For more information please visit: ventures.telus.com.

 

Cision View original content:https://www.prnewswire.com/news-releases/recoveryone-closes-33-million-series-c-financing-301376065.html

SOURCE RecoveryOne

Vonage SMS and Video APIs Power HIPAA-Compliant Hybrid Health Experiences to Enable Healthcare Organizations to Build Secure, Compliant Customer Communications

PR Newswire

HOLMDEL, N.J., Sept. 14, 2021 /PRNewswire/ — Vonage (Nasdaq: VG), a global leader in cloud communications helping businesses accelerate their digital transformation, has announced HIPAA-compliant SMS capabilities, powered by the Vonage Communications Platform (VCP). Now, Vonage enables healthcare organizations to deliver HIPAA-compliant solutions using both the SMS and Video APIs to provide patients with secure communications across their preferred channels.

Communications between patients and medical practitioners are central to today’s digital healthcare experiences – and this goes far beyond standard video conference platforms. Building a robust patient journey today includes video consultations, group discussion sessions, care and drug reminders, status notifications, critical alerts, and more. Leveraged together, the Vonage Video and SMS APIs allow these communications to be seamlessly embedded within healthcare providers’ existing healthcare applications.

Vonage implements security and data privacy best-practices by conducting independent third-party audits to confirm HIPAA-compliant status through the implementation of required security, privacy and data breach related safeguards for the protection of protected health information (PHI) when the APIs are used appropriately. Under the terms of HIPAA, Vonage acts as a “Business Associate” to healthcare customers, signing Business Associate Agreements (BAA) that specify each party’s responsibilities when it comes to PHI. The Company has provided BAAs for the Video API for years, enabling telehealth visits and consultations. Now, with the addition of HIPAA-compliant SMS capabilities, Vonage is powering the future of healthcare communications as the COVID pandemic has driven a fundamental shift in how people consume healthcare services.

“The world of healthcare has irrevocably changed since the onset of the COVID-19 pandemic, as patients and providers adapted and shifted to telehealth solutions,” said Jay Bellissimo, Chief Operating Officer, Vonage. “As we emerge from the pandemic, patients will continue to expect seamless, convenient digital experiences on their time and their preferred channels. By combining the Vonage Video and SMS APIs, providers have the power to build HIPAA-compliant patient communication journeys, offering security and personalized care at every touchpoint.”

Benefits to healthcare communications that leverage the Vonage SMS API include:

  • Automated Appointment Experience – Manage appointment scheduling easily via mobile appointment check-in and pre and post-visit text alerts.
  • Patient Relationship Management – Organizations can provide a higher standard of care with convenient mobile prescription notices, medical reminders, and important follow-ups.
  • Situation Readiness – Ensure staff and patients are alerted in real time during time-critical circumstances. Organizations can stay prepared with a secure text message solution that ensures targeted messages are sent and received.
  • Digital Surveys – Collect valuable patient feedback and continue to elevate their medical experience.
  • Authentication – Authenticate patients and ensure privacy and security – using Vonage’s trusted two factor authentication tools.

Learn more about how the Vonage Communications Platform can enable healthcare providers and organizations to build HIPAA-compliant customer communications and create innovative customer experiences.

About Vonage

Vonage (Nasdaq: VG), a global cloud communications leader, helps businesses accelerate their digital transformation. Vonage’s Communications Platform is fully programmable and allows for the integration of Video, Voice, Chat, Messaging and Verification into existing products, workflows and systems. Vonage’s fully programmable unified communications and contact center applications are built from the Vonage platform and enable companies to transform how they communicate and operate from the office or anywhere, providing enormous flexibility and ensuring business continuity.

Vonage Holdings Corp. is headquartered in New Jersey, with offices throughout the United States, Europe, Israel, Australia and Asia. To follow Vonage on Twitter, please visit www.twitter.com/vonage. To become a fan on Facebook, go to www.facebook.com/vonage. To subscribe on YouTube, visit www.youtube.com/vonage.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/vonage-sms-and-video-apis-power-hipaa-compliant-hybrid-health-experiences-to-enable-healthcare-organizations-to-build-secure-compliant-customer-communications-301375796.html

SOURCE Vonage

ThermoGenesis Awarded NIH SBIR Phase I Grant to Develop Key Cell Processing Disposable for Quintessence Automated manufacturing of Gene-engineered Autologous Cell (GEAC) Therapies

PR Newswire

RANCHO CORDOVA, Calif., Sept. 14, 2021 /PRNewswire/ — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company was awarded a $250,000 Phase I Small Business Innovation Research (SBIR) grant to develop and test the single-use sterile cell processing disposable, that will be used by the fully automated Quintessence System. These programs allow US-owned life science companies that are creating innovative technologies that align with NIH’s mission to improve health and save lives to engage in federal research and development that has a strong potential for commercialization. This technology is protected by 15 issued patents and 13 pending applications.

Philip Coelho, Chief Technology Officer (CTO) and Principal Investigator for this grant further explained: “Gene-engineered autologous cell (GEAC) therapies for hematologic cancers and inherited disorders are earning growing numbers of FDA approvals, but manufacturing inefficiencies (90+% scrap rates) contribute to long workflows and high costs. Current automation efforts do not offer a solution, because the cell processing techniques they automate are themselves inefficient (in terms of cell recoveries). This Phase 1 SBIR will validate the suitability of significantly more efficient cell handling processes enabled by our functionally closed X-Series® cell processing cartridge and X-BACS® buoyancy-based cell isolation reagents, recently licensed to Corning Life Sciences for global distribution. This enhanced cell processing cartridge will be integrated into a ‘one-pot’ GEAC manufacturing workflow lending itself to full automation in the simple, compact, moderately priced Quintessence instrument (the subject of a follow-on Phase 2 SBIR proposal.”

Existing X-Series cartridges are proven to enrich mononuclear cells from blood with target cell recovery efficiencies of 90-100% (for T cells and hematopoietic stem cells), and to wash or volume-reduce cell solutions with equal recovery efficiency. Similarly, X-BACS reagents used in X-Series cartridges prove up to 50% more efficient than conventional ferrous bead/magnetic field methods  at target cell isolation at very high purity. Combined, these innovations can offer at least a 6-fold improvement in cell yield relative to conventional techniques. Target blood cells thus prepared have been shown to be transduced with lentiviral vectors as readily as are conventionally produced target cells.

This Grant’s Specific Aims are: (1) to prototype and manufacture in small quantities an enhanced X-Series cartridge with additional features required to support the subsequent Aim; and (2) to validate and optimize the performance of all the steps of GEAC manufacturing (from blood to transduced, expanded and washed cells comprising a typical therapeutic dose) in a single such cartridge (‘one-pot’ workflow), the milestone for application for a Phase 2 SBIR to design and validate the Quintessence instrument that will fully automate that workflow.

About NIH SBIR Grants

The Small Business Innovation Research (SBIR) program allow US-owned and operated small businesses to engage in federal research and development that has a strong potential for commercialization. NIH’s SBIR program invests into health and life science companies that are creating innovative technologies that align with NIH’s mission to improve health and save lives. A key objective is to translate promising technologies to the private sector and enable life-saving innovations to reach consumer markets.

About ThermoGenesis Holdings, Inc.

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.

Company Contact: 

Wendy Samford

916-858-5191
[email protected]

Investor Contact: 
Paula Schwartz, Rx Communications
917-322-2216
[email protected]

 

 

 

Cision View original content:https://www.prnewswire.com/news-releases/thermogenesis-awarded-nih-sbir-phase-i-grant-to-develop-key-cell-processing-disposable-for-quintessence-automated-manufacturing-of-gene-engineered-autologous-cell-geac-therapies-301376089.html

SOURCE ThermoGenesis Holdings, Inc.

Color Star Technology Co., Ltd. (NASDAQ: CSCW) Launches Artificial Intelligence Capabilities on Color Star APP to Create “Parallel Universe”

PR Newswire

NEW YORK, Sept. 14, 2021 /PRNewswire/ — Color Star Technology Co., Ltd. (NASDAQ: CSCW) (hereinafter referred to as “Color Star” or the “Company”), an entertainment technology company focusing on the application of technology in the entertainment industry, today announces the launch of the first-edition artificial intelligence (AI) system on its global celebrity interactive platform, Color Star APP.

 

The current AI created by Color Star will focus on developing specific character images, where a particular image will be based on each registered user’s published works on the Color Star platform, including his or her music, dance, film, and animation works. This AI technology will also include capabilities and functions that can be used in the upcoming Color Star “map”, where users can shop, travel, and conduct business negotiations in virtual reality. The first-edition AI images launched will offer more than 1,000 image choices, and the scale of choices is still being expanded. In the future, more images will be launched for users to choose from.

Always committed to the application of entertainment technology, Color Star has continuously incorporated newer scientific and technological concepts into the Color Star APP software, combining entertainment with technology. With the launch of AI, the “parallel universe” concept espoused by the Company will gradually come to fruition. In the future, Color Star will further realize the concept of parallel universe through the implementation of augmented reality (AR) technology, which will allow a user to watch an online performance as if it were live. Users will also be able to interact and communicate with their favorite celebrities, and undertake activities such as shopping and business negotiations, all without leaving home. In addition, AI images in the Color Star APP will be used to represent and identify individual users on the internet. Through AI technology, one can overcome the limitations of reality, such as time, location, occupation, life circumstances, and so forth. Instead, each user will be able to create his or her own virtual universe with social interactions.

Mr. Basil Wilson, CEO of Color Star, commented: “Color Star has been making great efforts to develop products that can be combined with entertainment. For this purpose, we have set up a research and development base in Dubai. The Company’s AI system has completed its first phase of testing and application, with related products to be launched in succession; the new AR vision intelligence system currently under construction will also be launched in sequence. In the future, users will be able to realize a different self through Color Star regardless of their situation in the real world. This was one of our original goals in striving to create a parallel universe for our users.”

Color Star APP is currently available for direct download in both the Apple Store and Google Store. As Color Star’s applications are launched in batches, the Company believes it will bring more pleasant surprises and experiences to its global users.

About Color Star Technology

Color Star Technology Co, Ltd. (Nasdaq CM: CSCW) is an entertainment and education company that provides online entertainment performances and online music education services. Its business operations are conducted through its wholly-owned subsidiaries Color China Entertainment Ltd. and CACM Group NY, Inc. The Company’s online education is provided through its Color World music and entertainment education platform. More information about the Company can be found at www.colorstarinternational.com.


Forward-Looking Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements.  Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following:  the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the educational and training services market in 

China

 and other countries where CSCW conducts its business; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission.  For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at 

www.sec.gov

. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations or rules.

For more information, please contact:

William Tu

Skyline Corporate Communications Group, LLC
One Rockefeller Plaza, 11th Floor
New York, NY 10020
Office: (646) 893-5835
Email: [email protected] 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/color-star-technology-co-ltd-nasdaq-cscw-launches-artificial-intelligence-capabilities-on-color-star-app-to-create-parallel-universe-301375575.html

SOURCE Color Star Technology Co., Ltd.

Stifel Names David Rubulotta and Brant McDuffie Deputy Co-Heads of Fixed Income Capital Markets

ST. LOUIS, Sept. 14, 2021 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today announced the hiring of David Rubulotta and the promotion of Brant McDuffie as Deputy Co-Heads of Fixed Income Capital Markets. They will report to Eric Needleman, Global Head of Fixed Income Capital Markets.

David Rubulotta joins Stifel from Citigroup, where he most recently headed business development within Citigroup Global Markets’ fixed income division and also led leveraged finance sales. Prior to his time at Citigroup, he held senior roles with Lehman Brothers and Goldman Sachs. Mr. Rubulotta began his career at PricewaterhouseCoopers. He received an undergraduate degree from Villanova University and a Master of Business Administration from Columbia University. He is also a Certified Public Accountant.

“During his 25 years in the fixed income business, David has developed deep relationships with top institutional investors, financial sponsors, alternative asset managers, pension funds, and endowments while leading diverse teams and working in partnership with some of the sharpest minds in the fixed income universe,” said Mr. Needleman. “Understanding the needs of these clients has enabled him to identify investment trends and adapt the delivery of differentiated products and solutions that enhance accessibility to capital and drive performance. We are thrilled to have David bring that kind of focus to Stifel and our clients.”

Brant McDuffie, currently Head of Rates Sales, Trading and Research in Stifel’s Fixed Income Division, oversees the firm’s institutional fixed income brokerage business serving middle-market depositories, insurance companies, and money managers. He will maintain his current responsibilities while taking on this new role. Mr. McDuffie joined Stifel through its acquisition of Sterne Agee, where he served as Head of Fixed Income Capital Markets. Prior to Sterne Agee, McDuffie was a Director in Interest Rate and Currency Risk Management at Wachovia Bank. He earned a Bachelor of Arts in managerial economics from Hampden-Sydney College.

“Brant has been instrumental in helping grow the fixed income business at Stifel,” added Mr. Needleman. “Amidst challenging market conditions, we have steadily added to our sales effort, trading desks, and research groups, and prioritized the development of value-added products for our clients under Brant’s leadership. I am delighted to recognize his contributions with this well-deserved promotion, and I look forward to working with Brant and David in their new positions.”

Stifel Company Information

Stifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. Stifel’s broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated, including its Eaton Partners business division; Keefe, Bruyette & Woods, Inc.; Miller Buckfire & Co., LLC; and Stifel Independent Advisors, LLC. The Company’s broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and municipalities. Stifel Bank and Stifel Bank & Trust offer a full range of consumer and commercial lending solutions. Stifel Trust Company, N.A. and Stifel Trust Company Delaware, N.A. offer trust and related services. To learn more about Stifel, please visit the Company’s website at www.stifel.com. For global disclosures, please visit https://www.stifel.com/investor-relations/press-releases.

Stifel Media Relations Contact

Neil Shapiro, (212) 271-3447
[email protected]



SELLAS Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 28th

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will present at the 2021 Cantor Global Healthcare Conference to be held virtually on Tuesday, September 28, 2021, at 4:00 p.m. ET.

For more information about the conference, or to schedule a one-on-one meeting with SELLAS management, please contact your Cantor representative directly, or send an email to Cantor at [email protected] or KCSA Strategic Communications at [email protected].

About SELLAS Life Sciences Group, Inc.

SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes TNBC patients, following the standard of care.

For more information on SELLAS, please visit www.sellaslifesciences.com.

For more information, please contact:

Investor Contacts

Valter Pinto / Allison Soss
KCSA Strategic Communications
Email: [email protected]
Phone: 914.907.2675 / 215.272.2707

Media Contacts

Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
Email: [email protected]
Phone: 212.896.1241 / 212.896.1276



BIMI International Medical Inc. Signs Stock Purchase Agreement to Acquire Chongqing Zhuoda Pharmaceutical Co., Ltd.

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) — BIMI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), a leading healthcare products and services provider in China, today announced that it entered into a Stock Purchase Agreement (the “Agreement”) on September 10, 2021, to acquire Chongqing Zhuoda Pharmaceutical Co., Ltd. (“Zhuoda”), a wholesale supplier of pharmaceuticals and medical equipment, including over 1,220 pharmaceutical products, thousands of Chinese herbal medicines and more than 50 types of medical equipment.

Pursuant to the Agreement, BIMI will purchase all the issued and outstanding equity interests in Zhuoda in consideration of US$11,617,500 (RMB 75,000,000). At the closing, 2,200,000 shares of common stock of BIMI valued at RMB 43,560,000, or $3.00 per share (approximately US$6,600,000) will be issued as partial consideration for the purchase of Zhuoda. The remainder of the purchase price in the amount of approximately US$4,800,000 (RMB 31,680,000), is subject to post-closing adjustments based on the performance of Zhuoda in 2022 and 2023.

Mr. Tiewei Song, CEO and President stated, “We are encouraged and excited about the planned acquisition of Zhuoda, as we believe this transaction will be transformative for our Company and our shareholders. Zhuoda has established long-term strategic cooperation with 14 local hospitals, which account for most of the grade A tertiary hospitals in East Chongqing. It will greatly boost Company’s local market expansion.  

“The acquisition of Zhuoda represents a unique opportunity for BIMI and our shareholders to expand our product coverage, with BIMI’s commercialization expertise augmenting Zhuoda’s extensive products pipeline, large medical establishment customer base and their deep relationship with domestic and international medical device manufactures such as GE, Philips, LEPU and Landwind Medical. We are confident that this acquisition will create lasting value for our customers and will promote the growth of the company in a sustainable manner” concluded, Mr. Tiewei Song.


About BIMI International Medical Inc.

BIMI International Medical Inc. was founded in 2006. The Company is now exclusively a healthcare products and provider, offering a broad range of healthcare products and related services and operates five private hospitals in China. For more information, please visit 

www.usbimi.com

.


Safe Harbor Statement

Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to, the Company’s ability to achieve profitable operations, its ability to continue to operate as a going concern, its ability to continue to meet NASDAQ continued listing requirements, the effects of the spread of COVID-19, the demand for the Company’s products and services in the People’s Republic of China, general economic conditions and other risk factors detailed in the Company’s annual report and other filings with the United States Securities and Exchange Commission.


Investor Relations Contact:

Janice Wang
EverGreen Consulting Inc.
Email: [email protected]
Phone: +1 571-464-9470 (from U.S.)
+86 13811768559 (from China)